Detalles de la búsqueda
1.
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
N Engl J Med
; 388(18): 1657-1667, 2023 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37133585
2.
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.
N Engl J Med
; 389(23): 2125-2139, 2023 Dec 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37870968
3.
Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
Int J Cancer
; 154(5): 863-872, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37840339
4.
ADJUBIL: phase II study of adjuvant immunotherapy with STRIDE regimen with/without capecitabine in biliary tract cancers.
Future Oncol
; 20(6): 307-315, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38410920
5.
Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.
Oncologist
; 28(11): e981-e994, 2023 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37432264
6.
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
BMC Cancer
; 23(1): 470, 2023 May 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-37217885
7.
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.
Eur Radiol
; 33(2): 1174-1184, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35976398
8.
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Int J Cancer
; 150(1): 112-123, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34431518
9.
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Br J Cancer
; 127(5): 836-843, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35637412
10.
Sodium Thiosulfate Reduces Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy with Cisplatin: A Single-Center Observational Study.
Ann Surg Oncol
; 29(1): 152-162, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34350529
11.
FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.
BMC Cancer
; 22(1): 359, 2022 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35366831
12.
A Reduction of Calcineurin Inhibitors May Improve Survival in Patients with De Novo Colorectal Cancer after Liver Transplantation.
Medicina (Kaunas)
; 58(12)2022 Nov 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36556957
13.
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Int J Cancer
; 149(11): 1935-1943, 2021 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34310714
14.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Br J Cancer
; 124(3): 587-594, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33154570
15.
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306.
Ann Surg Oncol
; 27(7): 2389-2401, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32172334
16.
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
Anticancer Drugs
; 31(8): 856-865, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32639280
17.
[Prerequisites of magnetic resonance imaging for treatment planning in locally advanced rectal cancer - Interdisciplinary recommendations]. / Stellenwert und qualitative Voraussetzungen der Magnetresonanztomografie für die Therapieplanung beim lokal fortgeschrittenen Rektumkarzinom Interdisziplinäre Empfehlungen.
Z Gastroenterol
; 58(6): 577-582, 2020 Jun.
Artículo
en Alemán
| MEDLINE | ID: mdl-32544967
18.
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
Int J Cancer
; 145(2): 576-585, 2019 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30614531
19.
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT-ME-1 trial.
Int J Cancer
; 145(6): 1538-1546, 2019 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30801698
20.
Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial.
Blood
; 139(10): 1593-1597, 2022 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34932794